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Abstract
Background:  This paper proposes the use of decision trees as the basis for automatically
extracting information from published randomized controlled trial (RCT) reports. An exploratory
analysis of RCT abstracts is undertaken to investigate the feasibility of using decision trees as a
semantic structure. Quality-of-paper measures are also examined.
Methods: A subset of 455 abstracts (randomly selected from a set of 7620 retrieved from Medline
from 1998 – 2006) are examined for the quality of RCT reporting, the identifiability of RCTs from
abstracts, and the completeness and complexity of RCT abstracts with respect to key decision tree
elements. Abstracts were manually assigned to 6 sub-groups distinguishing whether they were
primary RCTs versus other design types. For primary RCT studies, we analyzed and annotated the
reporting of intervention comparison, population assignment and outcome values. To measure
completeness, the frequencies by which complete intervention, population and outcome
information are reported in abstracts were measured. A qualitative examination of the reporting
language was conducted.
Results: Decision tree elements are manually identifiable in the majority of primary RCT abstracts.
73.8% of a random subset was primary studies with a single population assigned to two or more
interventions. 68% of these primary RCT abstracts were structured. 63% contained pharmaceutical
interventions. 84% reported the total number of study subjects. In a subset of 21 abstracts
examined, 71% reported numerical outcome values.
Conclusion: The manual identifiability of decision tree elements in the abstract suggests that
decision trees could be a suitable construct to guide machine summarisation of RCTs. The
presence of decision tree elements could also act as an indicator for RCT report quality in terms
of completeness and uniformity.
Background
Introduction
Evidence-based medicine (EBM) asks that physicians con-
sult the most current scientific evidence to help them
answer clinical questions at the point of care [1,2]. The
primary evidence for the efficacy of treatments is often
documented in reports of randomized controlled trials
(RCTs). While there remains some debate about how
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applicable RCT results are to the broad population, due to
the strict entry criteria required to join them and the con-
founding effects of co-morbidities with individual
patients, good quality RCTs are designed to provide spe-
cific and statistically robust answers about the impact of a
clinical treatment or intervention on factors such as the
patients' prognosis or quality of life. As such, RCTs have a
crucial place in the development of the clinical evidence
base, and for now are the gold-standard in research design
for providing evidence of treatment effectiveness.
While much research has focused on developing technol-
ogies to assist clinicians to search for evidence [3-8], there
has been little attention paid to the more challenging text-
processing tasks of evidence extraction and summariza-
tion. As the biomedical literature continues to grow,
search technologies will probably need to be augmented
with such capabilities, to help identify key points in the
documents they retrieve, and ultimately summarize their
meaning for busy clinicians.
This paper proposes the use of decision trees as the basis
for automatically extracting critical information from
published RCT reports. We argue that decision trees, a
well-established construct in clinical decision analysis, are
an ideal macro-structure for representing and capturing
vital elements of RCTs. We report a detailed analysis of the
characteristics of a corpus of RCT reports. To assess the
feasibility of decision trees as a semantic structure or
meaning representation for machine extraction, we exam-
ine the quality of RCT reporting, the identifiability of
RCTs from abstracts, and the completeness and complex-
ity of RCT abstracts. We perform a series of analyses on a
corpus of randomly selected collection of RCT abstracts to
answer the following questions:
1. Are RCTs easily identifiable from the abstracts of pub-
lished reports on Medline?
2. How are RCT abstracts that contain decision tree ele-
ments structured? We are interested in the variation in the
pre-defined structures and the likelihood that the head-
ings can aid a reader or a computer algorithm in finding
decision tree elements.
3. How complex are the decision tree elements in RCT
abstracts with respect to study design and language of
reporting?
4. How complete is the reporting of decision tree elements
within RCT abstracts?
The ultimate goal of our work is to automate the processes
involved in creating meta-analyses which are multi-docu-
ment summaries that bring together the results from mul-
tiple RCTs into a single evidence-based recommendation.
Our analysis of RCT structure has a further purpose as it
suggests a method of automatically testing RCT reports for
quality, in terms of completeness, uniformity, and accu-
racy.
Information Overload in Evidence-based Medicine
The practice of EBM is hampered by the overwhelming
amount of information now available [9]. There are over
200,000 citation entries in PubMed with the Mesh Head-
ing "Clinical Trials". Their publication rate is exponen-
tially rising [10] with over 12,000 trials published in
2007. Furthermore, many have reported that clinicians
lack both the time and skills to locate and synthesize the
best evidence from the volumes of literature [9,11-14].
One strategy to alleviate this information overload is to
create secondary summaries of the evidence such as those
produced by the Cochrane Collaboration [15], Evidence-
based Medicine [16], the ACP Journal Club [17], and BMJ
Clinical Evidence [18]. Evidence-based Medicine and the
ACP Journal Club publish reviews that satisfy pre-defined
methods criteria. Cochrane and BMJ Clinical Evidence
aggregate and distil RCT outcomes into systematic reviews
and meta-analyses to guide best practice [19]. In particu-
lar, statistical meta-analysis is one of the most powerful
tools for deriving meaningful conclusions from some-
times conflicting reports and generating statistical power
greater than that of the individual studies [20-22].
Creating a systematic review requires a team of experts to
exhaustively sift through trial databases and published
reports of RCTs. The Cochrane Collaboration, arguably
the largest and best-equipped international organization
focused on extracting best clinical practice from research
practice, requires systematic reviews to meet stringent cri-
teria when selecting studies and collecting and analyzing
results. By 2000, the Cochrane collaboration had pro-
duced 795 systematic reviews covering 12,000 clinical tri-
als. Yet there had been 200,000 new trials added to its
database [23]. Clearly, the volume of published research
is growing at a rate that exceeds the human resources
available to systematically and comprehensively synthe-
size it [24].
This problem is further compounded as numerous studies
have identified deficiencies in the completeness and accu-
racy of some RCT reports [25-28] and as a result, there
have been concerted efforts to standardize the reporting of
clinical trials. Trial Bank [29] encourages registration in a
database through manual entry of descriptions of design
and execution, but only a small number of trials have
been archived so far. The CONSORT statement [30,31] is
gaining currency as an effort to improve the reporting ofBMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
Page 3 of 14
(page number not for citation purposes)
clinical trials through a checklist of 22 items and a partic-
ipant flow diagram.
Automated text mining and natural language processing
now holds the promise for easing the burden of effectively
summarizing such large volumes of medical knowledge.
An ongoing stream of research into summarization of bio-
medical research papers is tied to the resource intensive
manual mark-up and extraction methods. Georg et al.
[32] extend the well known Guideline Elements Model
(GEM) tool kit for medical document mark-up to support
the manual mark-up and extraction of if-then rules from
clinical guidelines. Aguirre-Junco et al. [33] take a similar
approach using mark-up tools to extract decision trees,
again from guidelines which already summarize expert
consensus.
Text mining for EBM is a growing area of research, with
researchers developing semantic search and evidence
summarization techniques for reranking search results
and locating and synthesizing clinical answers for clinical
practice [4,34-36]. The focus of all these efforts is on sup-
porting clinicians, and to our knowledge, no technology
support has been proposed that can assist systematic
reviewers to produce summaries and meta-analyses.
Demner-Fushman et al. [35] have used the PICO (Popu-
lation/Problem, Intervention, Comparison, Outcome)
Framework as a basis for extracting clinically relevant
information from Medline abstracts from core clinical
journals. PICO [37] was originally conceived as a method
to reformulate clinical problems into "well-built" ques-
tions that can be passed on to an information retrieval
engine, leading to improved precision and recall for find-
ing clinical answers. However, it has been reported that
questions posed by clinicians are not generally amenable
to a PICO formulation, and moreover, rephrasing ques-
tions does not increase success rates in finding answers
[38,39]. In recent work, Dawes et al. [40] investigated the
identifiability of PECODR (Patient-Population-Problem,
Exposure-Intervention, Comparison, Outcome, Results)
elements, an extension of the PICO framework, in medi-
cal journal abstracts.
In text mining, the granularity at which information
should be extracted is often a subject of debate. It is clear
that a complete semantic interpretation of language is
beyond the reach of current methods. In the clinical
domain, researchers have predominantly utilized
machine learning algorithms, particularly statistical classi-
fiers to extract information at the sentence level usually
within the abstract [35,41-43]. In some cases, researchers
pinpoint factual information within a document by iden-
tifying textual passages that follow scientific arguments
such as Purpose, Interpretation and Findings [44].
In our work, we attempt to exploit the strict design princi-
ples and stringent reporting guidelines for RCTs [45]
which provide us with domain-specific elements that can
act as semantic constraints for automated text extraction
algorithms. Further, successful machine extraction of the
RCT elements from a text could be used to signify a well-
written report or well-conducted trial, and could thus be
used as an automated quality assurance mechanism for
assessing the quality of RCT reports.
Decision Trees: Macro-structures representing RCTs
Medical decision science has long utilized decision trees
as the main representation for modelling decision
choices, and there is a substantial body of research behind
these trees making them general and powerful constructs
[46].
A decision tree [47] is a mathematical and visual represen-
tation of all possible decision options for a given choice,
and the consequences that follow each, usually expressed
in terms of likelihoods and utilities. For an RCT, a deci-
sion tree could compare the outcomes of competing ther-
apies for a given clinical condition.
Conventionally, decision trees are constructed by analyz-
ing the primary literature, which provides estimates for
event likelihoods. Where patient utilities are required,
standard methods are available to elicit robust numerical
estimates [47]. The experimental design of RCTs makes
them particularly amenable to be recast in decision tree
form. In Figure 1, we illustrate the derivation of a decision
tree from the participant flow diagram of an RCT, which
provides the tree structure, and the RCT outcomes, which
provide values for the outcome nodes of the tree. The par-
ticipant flow tree is determined by the intervention and
comparison experimental design, and the outcomes
measured for each patient group. It includes details such
as total participant numbers enrolled, excluded and
assigned as well as the number of evaluable patients. For
each comparison group, chance nodes split the tree to
report different outcome events. The derived decision tree
excludes participant information, and converts outcome
measures into a likelihood or probability.
The decision tree structure will vary according to the
number of randomized treatment groups or arms. A new
tree can be drawn for each primary or secondary outcome
that is analyzed. Whether or not a true decision tree can be
derived from the RCT report depends on how the out-
comes are defined. A common way of measuring outcome
is a binary measure (whether or not an event has
occurred). As in Figure 1, the resultant values compared
are frequency counts of occurrences at each arm which
could be converted to predictive probabilities, and thus
producing a "true" decision tree. Many other ways ofBMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
Page 4 of 14
(page number not for citation purposes)
measuring outcomes yield numerical values for each
treated subject, for instance, time to an event, continuous
values from physiological measurements, discrete numer-
ical values from frequency counts of events or standard-
ized scales (e.g. quality of life ratings). The tree structures
derived for these outcomes will be intermediate represen-
tations from which further statistical analyses are required
to convert outcome values to probabilities to populate a
true "decision-ready" tree. Figure 2 illustrates one example
of such an intermediate decision tree.
The decision trees described above can have a dual use.
For systematic reviewers, decision trees can answer ques-
tions about study design and detail intervention out-
comes. Extracted decision trees from multiple studies may
even be combined to help expert reviewers conduct meta-
analyses by synthesizing outcomes. For medical practi-
tioners, decision trees can be directly integrated into deci-
sion support systems used at the point of care.
Methods
Corpus Collection
A corpus of RCT abstracts was compiled by conducting a
PubMed search, specifying RCT in the publication type
field. To obtain a representative cross-section of clinical
conditions, the following keywords were used: asthma,
Example tree structure from an RCT (PMID: 12637461) Figure 1
Example tree structure from an RCT (PMID: 12637461). The tree compares tamoxifen treatment with tamoxifen plus 
aminoglutenthimide for postmenopausal breast cancer patients. The primary outcome measure is 5 year disease free survival 
(DFS), whose numerical values can directly be utilized in decision analysis. The corresponding true decision tree is illustrated.
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diabetes, breast cancer, prostate cancer, erectile dysfunc-
tion, heart failure, cardiovascular, angina. This yielded
7620 abstracts (Group A).
A smaller subset of 455 abstracts (Group B) was randomly
selected for detailed analysis and annotation. These
abstracts were sourced from 197 different journals dating
from 1998 and 2006.
Identifiability of RCTs: Categorization of Studies Labelled 
as RCTs
Not all the documents labeled as RCTs by Medline are
genuine RCTs. To determine whether RCTs can easily be
found via PubMed, we manually labeled the RCTs in
Group B. Abstracts were first divided into Group R (pri-
mary RCT reports, and excluding studies that were not
truly randomised e.g. quasi-random methods of alloca-
tion) and Group N (publications that are not primary
reports), and further subdivided into the following six cat-
egories:
• R1: Primary reports of single RCTs with full descriptions
of study design and outcomes.
￿ R2: Primary reports of RCTs with a complex sequence of
intervention or randomization phases or a complex com-
bination of multiple RCTs.
￿ R3: Sub-studies of RCTs, which generally include
descriptions of study design, and focus on specific out-
come measures and data analyses. Reports in this group
(follow-up reports, updates, sub-group and post-hoc anal-
yses) often describe larger scale studies whose methodol-
ogies (recruitment etc) have been described in detail in
previous reports.
￿ N1: RCT protocols or announcements, often with only
partial description of recruitment strategies, baseline char-
acteristics and methodology with no results.
￿ N2: Systematic reviews of one or more trials, including
pooled analyses.
￿ N3: Other studies, (population studies, retrospective
reviews and non-randomized studies).
The manual categorization was performed by GYC. A ran-
dom subset of 50 articles was assigned to a domain expert
(a systematic reviewer) to arrive at category definitions
Example intermediate decision tree derived from an RCT (PMID: 16782917) Figure 2
Example intermediate decision tree derived from an RCT (PMID: 16782917). The primary outcome measure is the 
median Progression Free Survival (PFS) time, computed for each group in each treatment arm. The output decision tree taken 
directly from the article is an intermediate representation as opposed to a true "decision-ready" tree structure.
7.1 months 
N=196  
women with HER-2 
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N=98 trastuzumab 
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and carboplatin 
N=92 
evaluable
N=94 
evaluable 
10.7 months 
Outcome Measure= Median PFS time
Outcome 
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and perform an inter-rater reliability assessment, meas-
ured by Cohen's kappa [48]. During categorization, all
abstracts were assumed to be primary reports of RCTs
unless it was apparent in the abstract that they were not.
Analysis of Structured Abstracts
The variation in the structured abstracts in both the large
corpus (Group A) and the hand labeled primary RCT
abstracts (R1) were examined. Abstracts were first classi-
fied as structured or unstructured, based on the presence
of labeled headings appearing within the structured
group. Abstracts identified as being structured were fur-
ther analyzed to identify the number and type of unique
headings used, and variations in the order of reporting of
these subheadings. Some headings differed in the terms
they contained, but were otherwise semantically identical
(e.g. "Setting", "Study Setting"). To assist with analysis,
the full list of unique headings was condensed into a
shorter list of semantic equivalent heading classes.
Study of Decision Tree Elements: Complexity, 
Completeness and Identifiability
Abstracts in R1 were analyzed, looking for the presence,
location, and type of key decision tree elements. Conven-
tionally, RCTs can be distinguished by many elements
that follow the well-documented principles of sound trial
design [45]. Examples are the design of the randomized
assignment (conventional, crossover, parallel group, 2 × 2
factorial) or the method of blinding (single or double
blinded, open label). These study design variations are
generally recognizable from the key words in the descrip-
tions. The adequacy in their reporting have been explored
elsewhere [25,26]. From the standpoint of automatic
processing, we are presently interested in characterizing
how the comparison of interventions, the assignment of
population groups and measurement of outcome values
are reported. For each of the three elements, we examine
the variation in complexity across our set of RCTs, the var-
iation in completeness of their reporting in abstracts and
if they are identifiable particularly in structured abstracts.
Along each of the above dimension, each abstract is
assigned to several subcategories.
For intervention information, abstracts in R1  were
assigned to two subcategories:
I1: Pharmaceutical interventions where drugs are com-
pared in each arm. A placebo is often allocated at one arm.
I2: Non-pharmaceutical interventions such as surgical pro-
cedures, behavioral therapies, or multi-modal strategies. A
control or usual-care group is often allocated at one arm.
For population information, the complexity of popula-
tion assignment in the study design was studied. Each
abstract in R1 was assigned to the following:
P1: A single patient group defined by some criteria, with
subjects randomly assigned to each treatment arm.
P2: A single patient group with one (or more) additional
non-randomized control group(s), corresponding to
additional arm(s) in the tree. For instance, one control
group can be age and gender matched healthy cohorts.
P3: Multiple patient groups defined according to some cri-
teria prior to randomization. Results for each patient
group are usually analyzed together and separately, and
compared.
For outcome information, the following categories were
given to the abstracts:
O1: One or more explicit primary outcome variables are
identified from the abstract, including the outcome values
to form decision trees.
O2: Partial values of the primary outcomes are identified
from the abstract and the remainder can be elicited from
the text of the article to complete decision trees.
O3: One or more explicit primary outcome variables are
identified from the abstract, but no numerical values are
provided and only qualitative statements about polarity
of outcomes.
GYC performed category assignments for abstracts in R1.
A team of three clinically trained annotators identified the
interventions being compared, and the population counts
(the total number of subjects, the number assigned at an
arm of the study and the number lost to follow up or drop
outs) from the texts. The sentences which describe the
assignment of each treatment to each comparison group
are also labeled, as these sentences would be the basis for
any extraction of information to create a decision tree.
Annotators underwent training sessions using test
abstracts to ensure common understanding of sentence
classes. Where there was a disagreement about sentence
annotation class within a given abstract, a consensus
annotation was agreed. For outcomes, a randomly
selected subset of 21 abstracts is analyzed and the out-
come values are labeled. For each of the three elements
(intervention, population group and outcome), a qualita-
tive analysis was performed, examining the distribution of
information across headings used within the structured
abstracts.BMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
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Results
Identifiability of RCTs: Categorization of Studies Labeled 
as RCTs
The number of abstracts in each subcategory of 455 Group
B abstracts is summarized in Table 1. Within this corpus,
86% (391/455; Group R) were identified as RCTs and
14% (64/455; Group N) were not strictly primary RCT
reports. Most of the RCT reports were primary reports of
single RCTs (73.8%; Group R1). The studies in Group N
were predominantly population studies within subgroup
N3. Inter-rater agreement (Cohen's kappa [48]) for this
assignment task was 0.826 (25 in disputed set), and a final
agreement was arrived at with the disputed set.
Only a small portion (4.6%; R2) of the RCTs were com-
plex reports of multiple RCTs. Some of these contained
multiple randomization phases within a single study,
together with multiple patient groups. It was often diffi-
cult to ascertain from these abstracts the number of treat-
ment arms or precisely which stages of the study were
randomized and which were not, and reporting of out-
comes are equally complex e.g.:
"At baseline, 294 subjects were randomized to receive either
placebo first (n = 139) or inactivated trivalent split-virus influ-
enza vaccine first (n = 155). Study subjects were categorized
into 2 groups: subjects in group 1 (n = 148) were receiving
medium-dose or high-dose inhaled corticosteroids (ICSs) or
oral corticosteroids, whereas subjects in group 2 (n = 146) were
not receiving corticosteroids or were receiving low-dose ICSs. ...
Serologic responses to each influenza vaccine antigen were sig-
nificantly higher in vaccine than in placebo recipients and were
similar among influenza vaccine recipients in groups 1 and 2
for the following endpoints: rise in antibody titer, percent of
participants who developed a serological response, and percent
of subjects who developed a serum hemagglutination inhibition
antibody titer > or =1:32." PMD: 15100679.
The descriptions in R3 (RCT substudies) varied considera-
bly because this group encompasses a large variety of stud-
ies. These include updates of results, follow-on studies, or
post-hoc analyses which could include comparisons of
subgroups or analyses of secondary outcomes.
Analysis of Structured Abstracts
Over half the abstracts were structured, in Group A (58%;
4441/7620) and in the primary RCT reports Group R1
(68%; 230/336) (Table 2). In Group A, there were 238
unique section headings which were however often
semantically equivalent, and could be manually mapped
to each other. Manual mapping into equivalence classes
condensed the section headings into 106 classes. Exam-
ples of these mappings are shown in Table 3.
After class mappings, there were 400 different sequence
patterns in the combinations of section headings, with
over 90% of these variations occurring less than 10 times.
The most common section heading patterns, and some
rarer patterns, are shown in Table 4. The variation in struc-
tural ordering was large, and many of the heading names
were unique. A typical heading sequence is "Background,
Aim, Methods, Results, Conclusions" but there were many
compound headings such as "Method/Results", "Results/
Conclusion", "Subjects/Settings" etc. Most of the varia-
tion in heading substructure was generated in reporting
the breakdown of experiment design, for example, "Sub-
jects", "Setting", "Patients", "Intervention", "Outcome
Measures" etc. The exact sequence and combination of
these headings differ greatly across abstracts. In Table 2,
the number of abstracts containing a distinct heading for
intervention, population and outcome measures are
reported for Group A and R1. Only a very small portion of
abstracts have all three distinct sub-headings (2.2% of
Group A and 3.3% of R1).
Study of Decision Tree Elements: Intervention Information
Of the abstracts in R1 (single RCT report), 63% of inter-
ventions were pharmaceutical (I1) and 37% non-pharma-
ceutical (I2) (Table 5). In terms of complexity, most
abstracts reported only 2 treatment arms in the study.
(76% in I1 and 78% in I2). In terms of completeness, only
one abstract in each subgroup gave no indicator of the
number of treatment arms in the study.
In many abstracts, multiple sentences were identifiable as
intervention sentences. Of the 106 structured abstracts in
R1, there are 254 intervention sentences. Table 6 reports
the location of the sentence(s) describing assignment of
intervention at each arm within the structured abstracts in
R1, with respect to the mapped heading class.
Table 1: Number of abstracts in each subcategory in a randomly selected corpus of 455 RCT abstracts.
Classes Total R1 R2 R3 N1 N2 N3
Single RCT Complex RCT RCT substudy RCT protocol or 
announcement
Systematic review Other study
N (%) 455 336 (73.8%) 21 (4.6%) 34 (7.5%) 5 (1.1%) 6 (1.3%) 53 (11.6%)BMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
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The intervention was described in the Method section
(78%), in Aim (5.5%), Design (3.1%) or Results (0.1%).
When there is no method section, 30% of intervention
sentences appear in the Aim and 60% in Design. The
intervention is mentioned 100% of the time under Inter-
vention if that heading exists. Even when there is a
Method section, the explicit mention of intervention is
not guaranteed to be there.
We perform a qualitative analysis of the language used to
describe the comparison of intervention. Most (96.7%;
206/213) abstracts in I1(pharmaceutical intervention)
describe the randomized assignment of treatments within
a single sentence, e.g.:
"Following a 3-week, single-blind placebo run-in period, eligi-
ble patients were randomized to receive either manidipine 10
mg or enalapril 10 mg once daily for 24 weeks." PMID:
15811479.
These intervention sentences tend to embed additional
information about methodology such as duration of run-
in period or treatment period and dosage. They occur fre-
quently as compound noun phrases. The actual compari-
son details can be described in parenthetical remarks e.g.:
"Patients were randomly allocated to treatment with talinolol
(100, 200 or 300 mg once daily) or placebo .."
PMID:15726874.
The description of assignment of treatments to various
groups was often more complex in I2 (non-pharmaceuti-
cal intervention), using multiple sentences. There were 18
abstracts (14.6%; 18/123) which describe randomization
and assignment to groups in 2 to 5 sentences e.g.:
"Diet intervention was performed by telephone counseling and
promoted a low fat diet that also was high in fiber, vegetables
and fruit. The comparison group was provided with general die-
tary guidelines to reduce disease risk .." PMID: 11148556.
Of the remaining I2 abstracts (85%; 105/123), assignment
of intervention is described in one sentence. Among these,
the specification of the intervention procedure varied in
detail and was often underspecified. The actual interven-
tion procedure might be described further in the abstract
Table 2: The number of unstructured and structured abstracts in Group A, the original set of abstracts and Group R1, the primary 
RCT reports from the randomly selected subset.
Number of Abstracts in A Number of Abstracts in R1
Total abstracts 7620 (100%) 336 (100%)
Unstructured abstracts 3179 (42%) 106 (32%)
Structured abstracts 4441 (58%) 230 (68%)
Structured abstracts with explicit heading for intervention 283 (3.7%) 14 (4.2%)
Structured abstracts with explicit heading for population 433 (5.7%) 17 (5.0%)
Structured abstracts with explicit heading for outcome measures 329 (4.3%) 18 (5.3%)
Structured abstracts with explicit heading for all three subheadings 162 (2.2%) 11 (3.3%)
Table 3: Examples of equivalence classes of pre-defined sub-headings in structured abstracts.
Class Example Heading Names
Aim Goal, Aim of the study, Purpose
Setting Setting, Study setting, Settings and Location
Participants Study population, Type of participants, Patients or participants, Sample
Outcome measure Measurements, Primary outcome measure, Study endpoints, Major outcome measuresBMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
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or elsewhere, possibly only in the article because these
interventions can be quite complex to describe in full in
the abstract e.g.:
"Forty-four women were randomly assigned to receive either a
lifestyle change or a lifestyle change with self-control skills
intervention." PMID: 15186658.
A substantial number of I2 abstracts (19.5%; 24/123)
mention the assignment of intervention in a sentence, fol-
lowed by one or more sentences which describe the
groups, e.g.:
".. 277 women diagnosed with CVD (mean age 61 +- 10
years) were randomly assigned within 1 of 12 San Francisco
Bay Area hospitals to a usual-care group (UG; n = 135) or
intervention group (IG; n = 142). ..The UG received strong
physician's advice, a self-help pamphlet, ... The IG received
strong physician's advice and a nurse-managed cognitive
behavioral relapse-prevention intervention at bedside ..."
PMID: 14769679.
Study of Decision Tree Elements: Population Information
The population subcategories reflect on the complexity of
RCT study designs and reporting. Table 7 reports the num-
bers abstracts within each subgroup of population charac-
teristics. 95% (320/336 in P1) of these are simple RCTs
with a single population group with subjects randomly
assigned to two or more treatments.
Reporting of patient characteristics in P2 and P3 was more
complex because abstracts included the number of
patients, age and gender, inclusion criteria and sometimes
baseline characteristics are for each group. The outcomes
for the groups might be analyzed separately or together.
Effectively this would result in a distinct decision tree for
to each population group e.g.:
"A total of 244 T3 – 4 M0 patients and 200 T1 – 4 M1
patients were randomized to either OE or PEP therapy. .. In the
T3 – 4 M0 patients, the treatment (PEP versus OE) and the
presence of pretreatment vascular diseases were statistically sig-
nificantly associated with a risk of CV complications (p = 0.01
Table 4: Examples of the patterns that occur in the section headings of structured RCT abstracts of Group A.
Structure of Abstracts % of Corpus
Background, Method, Result Conclusion 16
Aim, Method, Result, Conclusion 14
Aim, Patient and Method, Result, Conclusion 8.5
Background, Aim, Method, Result, Conclusion 7.6
Background, Method and Results, Conclusion 6.6
Aim, Participants, Design, Measurements, Result Conclusion < 1
Context, Design, Setting, Participants, Outcome Measures, Result, Conclusion < 1
Aim, Design and Setting, Participants, Intervention, Measurements and Main Results, Conclusion < 1
Table 5: Intervention information for primary RCT abstracts (R1).
Pharmaceutical intervention (I1) Non-pharmaceutical intervention (I2)
Total abstracts 213 123
Number of treatment arms unknown 1 1
2 treatment arms 161 96
3 treatment arms 33 20
4 or more treatment arms 5 6BMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
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and 0.003, respectively). In the T1 – 4 M1 patients, such an
association was not found." PMID:1626166.
The completeness in the report of population counts was
also studied. Most abstracts (84%) specified the total
number of participants in a study (Table 8). However,
whether the number refers to the population at recruit-
ment, enrolment, assignment or completion varied from
one abstract to another. It can be expected that the num-
bers at each stage of the trial are different, but this infor-
mation is often ambiguous in the abstract or buried
within the text of the article. At times the stage of the trial
(enrolment or evaluation etc) associated with the popula-
tion number is not specified. In the following example,
population information was given under the Patients sub-
heading:
"Patients: Twenty-five mono-opioid addicted patients with mild
to moderate systemic disease (ASA II classification) in a meth-
adone substitution program." PMID:10809268.
Information that specifies the number of evaluable
patients at follow-up is critically important in determin-
ing outcomes. Of the 280 abstracts that provide the total
number of subjects, only 50 of them explicitly report the
number of "evaluable" patients at completion or follow-
up. Of the 50, 40 report two or more numbers, referring
to assignment or enrolment as well as follow-up, and 10
report only the number at completion.
From Table 8, 122 (36%) abstracts report the number of
patients allocated to each arm of the trial. Of the 214
abstracts that do not report numbers at each arm, 46 have
crossover designs.
Table 9 shows the location of the annotated instances of
population values in structured abstracts, revealing that
population information is most often found in the
Method section or sections related to experimental design,
although it is not universally the case.
Study of Decision Tree Elements: Primary Outcomes 
Measures and Values
Of the 21 abstracts examined, 15 abstracts (71%) indicate
the primary outcome measures as well as the values so
that a decision tree could be elicited directly (Table 10). In
7 of the 15 abstracts in O2 (partial outcome measures and
values), the primary outcome measures were binary
events, and could be converted to probabilities for deci-
sion analyses. Example outcome events included: objec-
tive response rate, progression-free survival, 5-year disease
free survival, clinical benefit rate. For 8 of the 15 abstracts
the primary outcome measures could not be directly con-
vertible to probabilities. Example outcome measures
included: treadmill exercise time, measurements with
biomarkers such as blood pressure, glucose levels. In gen-
eral, outcomes can be reported as the differential in the
measurement, given as a percentage or a literal value,
along with a (usually 95%) confidence interval and/or a p
value. Otherwise the measurement (as a mean and stand-
ard deviation) at baseline and at follow-up can be pro-
vided for each group. Often, additional statistical
measures are given such as odds or hazard ratio. In all, the
outcomes can be reported in multiple sentences or in a
single sentence with numerical values within parentheti-
cal remarks. e.g.:
"Baseline values were: 24 hour UAE [geometric mean (95%
CI)] 134 (103 to 170) mg/24 hours, ambulatory blood pres-
sure [mean (SD)] 140 (10)/77 (7) mm Hg, and GFR 103
(19) mL/min/1.73 m2. Reductions in UAE from baseline were
52% (46% to 57%), 49% (43% to 54%), and 59% (54% to
63%) with increasing doses of irbesartan (P < 0.01)." PMID:
16105050.
Table 6: Distribution of sentences describing interventions and 
comparisons with respect to the classes of pre-defined 
subheadings in primary RCT structured abstracts (R1).
Heading Class Number of Intervention Sentences
Method 197 (78%)
Intervention 19 (7.5%)
Aim 14 (5.5%)
Method and Results 12 (4.7%)
Design 8 (3.1%)
Results 2 (0.1%)
Background 1 (<0.1%)
Setting 1(<0.1%)
Table 7: Number of abstracts in each sub-category for population treatment for 336 primary RCT abstracts (R1)
single patient group rand-
omized (P1)
single patient group randomized, addi-
tional control group (P2)
more than one patient group ran-
domized (P3)
Number of abstracts 320 11 5BMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
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4 abstracts provide only qualitative descriptions of the
effect of an intervention, sometimes with p values e.g.:
"Main Outcome Measures: Any limitation in activity was the
primary outcome.. Results: After adjusting for covariates, the
odds of having any limitation in activity during the 90 day trial
were significantly (P = .03) lower for children randomized to
the Health Buddy." PMID: 11814370.
In all cases, outcome statements with numerical values are
found in the Results sections of structured abstracts.
Discussion
Our initial analysis has shown that decision trees ele-
ments are manually identifiable from RCT abstracts; that
for the majority of them, the study design can in principle
be extracted as a decision tree, and that some complete
decision trees are indeed extractable from RCT abstracts.
Identifiability of Abstracts
Most abstracts found in the documents we retrieved from
the Medline database were primary reports of RCTs, but it
is clear that a simple search of RCT reports yields results
that are corrupted by other types of studies. To increase
precision in the search for RCTs, more complex search fil-
ters are needed to exclude trials that are not genuine RCTs.
There is mixed prior evidence that structured abstracts
[49] improve information retrieval and readability as
intended [50-52]. Some have reported that abstract struc-
ture can be inconsistent with missing sections [53-55]. We
have found here that the sequence of pre-defined head-
ings varies widely, and the location of the critical elements
for RCTs such as the comparison of intervention and pop-
ulation numbers cannot be reliably located according to
the names of sub-headings. Specifically relevant headings
such as Intervention, Patients, Outcome Measures, are not
rare. In the past, researchers have used machine learning
methods to classify sentences in unstructured abstracts
according to the generic headings of Aim, Method, Results
and Conclusion [41-43]. We speculate that like structured
abstracts, key facts in unstructured abstracts such as inter-
vention and population are not necessarily located in
what would be considered a Method sentence.
Complexity
A sizeable portion of our corpus of studies consists of sim-
ple RCTs with a single population group assigned to two
or more interventions. The reporting of pharmaceutical
interventions appears to be simpler and more consistent
than non-pharmaceutical interventions in the abstract.
The reporting of outcomes can also vary in complexity,
depending on the amount of detail provided in the
Table 8: Overall population information for primary RCT abstracts (R1).
Number of abstracts
Abstracts reporting total subjects in study 280 (84%)
Abstracts reporting subjects assigned to each arm 122 (36%)
Abstracts reporting the number of drop outs 5 (1.5%)
No information about population 20 (6%)
Table 9: Distribution population information with respect to the classes of pre-defined subheadings in structured abstracts.
Total number of instances of population values
Method 195
Intervention 3
Aim 3
Method and Results 22
Design 16
Results 82
Patients 15BMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
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abstract. An automatic extraction algorithm would need
to interpret numerical values and assign the correct set of
measurements to each respective arm.
For RCTs that concern more than a single population (P2)
or a complex sequence of treatments or randomization
phases (R2), the decision tree could be multi-layered with
separate branches for each population group. This would
pose a more challenging problem from an automated
extraction point of view because of the many different
configurations that are possible.
Completeness
For primary RCT abstracts (R1), a simple decision tree rep-
resentation could at least be partially instantiated. Infor-
mation about the comparison of intervention can be
found in the abstract but there is more variation in report-
ing of population counts in terms of completeness. In our
examination of outcome values, most abstracts provide
the numerical values for the primary endpoints although
a few only provide qualitative or interpretative statements
of their findings.
From the standpoint of automated processing, it will at
least be necessary to use the full text for complete decision
trees in many cases, particularly if all decision trees with
respect to all endpoints or assessments are desired. How-
ever, it is beyond our scope to assess the difficulty of
extracting complete decision trees from the full text. It will
also be necessary for an automated algorithm to disam-
biguate among all the population counts that are given in
order to interpret a trial properly and to infer which criti-
cal pieces are in fact missing from the reporting.
Quality of Reporting
There is mixed evidence of the impact of efforts such as
CONSORT on the quality of RCT reporting [29,32,56,57].
It may be possible that further to CONSORT, another met-
ric for measuring the quality of reporting is whether full
decision trees can be elicited from the abstract (by hand or
by machine), particularly for primary reports of simple
RCTs. We argue that inclusion of elements of decision
trees could be a reasonable additional prescription for
what should be reported in RCT abstracts. For instance,
the explicit inclusion of factors, such as population counts
at each stage and numerical outcome measurements cor-
responding at each arm, would not only improve reada-
bility but would ease the task of automatic information
extraction that could lead to applications that enhance
semantic search and automatic summarization.
Limitations
In proposing the use of decision trees as an underlying
semantic representation, this study has outlined a basic
approach to representing the critical elements of interest
in RCT studies. However, reviewers may need to examine
many other methodological details such duration of trial,
follow up period, secondary outcomes such as adverse
events, toxicity, and side effects, or statistical computa-
tions such as odds ratios, hazard ratios, and so on. These
are factors which should ideally be automatically
extracted in a text processing system as well as the basic
decision tree structure in order to answer all the questions
that may arise.
In our analysis, the authors automatically computed the
number of structured abstracts in Group A by a method
that uses regular expressions to look for section headings.
This method was not evaluated and some errors may
potentially exist.
Our data analysis is a preliminary study to characterize
RCT reports across a set of typical conditions. A more
detailed analysis using larger data sets may provide more
insight into the reporting of factors such as intervention,
outcomes and population in abstracts. An extensive study
of full articles is also necessary to reveal whether this
information can be extracted reliably. A larger data set
would be necessary for full annotation for the purpose of
training classifiers for machine extraction. Finally, many
RCTs are not indexed in the Medline database and we rec-
ognize that our data set may not be representative of all
the data available to systematic reviewers.
Conclusion
This paper has proposed the use of decision trees as repre-
sentation of RCT reports to support automated extraction
of the critical elements of RCTs, and subsequent machine
summarization.
In an analysis of a corpus of randomly selected abstracts,
we found that decision tree elements can be elicited man-
ually from the majority of RCTs returned from a search on
Medline. We have also suggested that a complete report of
Table 10: Number of abstracts in each sub-category for reporting of outcomes
O1
Full primary outcome measures and 
values
O2
Partial primary outcome measures and 
values
O3
numerical outcomes not translatable into a 
chance node
Number of abstracts 15 2 4BMC Medical Informatics and Decision Making 2008, 8:48 http://www.biomedcentral.com/1472-6947/8/48
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these parameters in RCT abstracts is an important quality
measure for comprehensibility for humans and process-
ing by machine. We are currently in the process of devel-
oping annotation guidelines and annotating components
of decision trees from the full text of RCT reports. Future
work will be the implementation of a system for automat-
ically extracting decision tree components and presenting
the results in a graphical format.
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